• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Jasper Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    7/3/25 4:01:34 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JSPR alert in real time by email
    false 0001788028 0001788028 2025-07-03 2025-07-03 0001788028 JSPR:VotingCommonStockParValue0.0001PerMember 2025-07-03 2025-07-03 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsMember 2025-07-03 2025-07-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): July 3, 2025

     

     

     

    JASPER THERAPEUTICS, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-39138   84-2984849
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2200 Bridge Pkwy Suite #102

    Redwood City, California 94065

    (Address of Principal Executive Offices) (Zip Code)

     

    (650) 549-1400

    Registrant’s telephone number, including area code

     

    N/A

    (Former Name, or Former Address, if Changed Since Last Report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    (Title of each class)   (Trading Symbol)   (Name of exchange on which registered)

    Voting Common Stock, par value $0.0001 per share

      JSPR   The Nasdaq Stock Market LLC

    Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

      JSPRW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On July 3, 2025, Jasper Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 12,014,527 shares of the Company’s voting common stock, or approximately 80% of the 15,022,122 shares of the Company’s voting common stock issued and outstanding as of May 9, 2025, the record date for the Annual Meeting, were represented virtually or by proxy.

     

    At the Annual Meeting, the Company’s stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 19, 2025.

     

    Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

     

    Proposal No. 1: To elect three Class I directors to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified.

     

    Director Nominee   Votes For   Votes Withheld   Broker Non-Votes
    Kurt von Emster   8,467,774   186,265   3,360,488
    Scott Brun, M.D.   8,612,491   41,548   3,360,488
    Vishal Kapoor   8,567,506   86,533   3,360,488

     

    Proposal No. 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2025.

     

    Votes For   Votes Against   Abstentions
    11,992,658   18,646   3,223

     

    Proposal No. 3: To approve, on an advisory basis, the compensation of the Company’s named executive officers.

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    8,108,299   536,022   9,718   3,360,488

     

    Proposal No. 4: To approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers.

     

    Every One Year   Every Two Years   Every Three Years   Abstentions   Broker Non-Votes
    8,580,886   5,444   29,171   38,538   3,360,488

     

    In light of the Company’s stockholders voting on an advisory basis to hold future advisory votes on the compensation of the Company’s named executive officers every one year, the Company has determined that it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. 

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    JASPER THERAPEUTICS, INC.

         
    Date: July 3, 2025 By: /s/ Herb Cross
        Name:  Herb Cross
        Title: Chief Financial Officer

     

    2

     

    Get the next $JSPR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JSPR

    DatePrice TargetRatingAnalyst
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    7/8/2024$90.00Buy
    BTIG Research
    6/27/2024$86.00Buy
    Stifel
    5/6/2024$65.00Buy
    H.C. Wainwright
    4/3/2024$65.00Outperform
    Evercore ISI
    3/28/2024$70.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Jasper Therapeutics with a new price target

      UBS initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $38.00

      2/13/25 8:09:46 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Jasper Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $63.00

      12/6/24 7:52:11 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Jasper Therapeutics with a new price target

      JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00

      9/9/24 7:39:14 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brun Scott C.

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      7/3/25 4:25:47 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Emster Kurt Von

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      7/3/25 4:24:56 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shizuru Judith Anne

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      7/3/25 4:24:09 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Carlyle Group Inc. bought $2,460,500 worth of Voting Common Stock (190,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/12/24 6:23:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Velan Capital Investment Management Lp bought $4,532,500 worth of shares (350,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/9/24 8:40:05 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiggans Thomas G bought $6,486 worth of Voting Common Stock (10,000 units at $0.65), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      11/30/23 4:05:16 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    SEC Filings

    See more
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      7/3/25 4:01:34 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      6/16/25 6:19:34 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Jasper Therapeutics Inc.

      DEFA14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:02:13 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

      11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell drive

      6/14/25 10:00:23 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

      REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in cold

      6/3/25 8:00:39 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics to Present at Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences: RBC Capital Markets 2025 Global Healthcare Conference Conference Dates: May 20-21, 2025Presentation Date/Time: Wednesday, May 21, 2025; 11:00 a.m. EDTPresentation Format: Fireside Chat Jefferies 2025 Global Healthcare ConferenceConference Dates: June 3-5,

      5/14/25 4:30:00 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

      REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

      6/19/24 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

      REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

      11/1/23 8:00:00 AM ET
      $DERM
      $JSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Jasper Therapeutics Strengthens Management Team with Key Appointments

      Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

      8/2/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Financials

    Live finance-specific insights

    See more
    • Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

      11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell drive

      6/14/25 10:00:23 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

      Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t

      1/8/25 7:00:37 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

      14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci

      10/14/24 7:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 6:01:49 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 3:32:57 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/4/24 12:05:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care